Patent Document ID: 20050244890
Application ID: 10982545
Patent Status: 0

Claim One:
1. A method for qualifying Alzheimer's disease status in a subject comprising: a. measuring at least one biomarker in a biological sample from the subject, wherein the at least one biomarker is selected from the group consisting of M60464.7 (Hemopexin), M3513.9 (7B2 CT fragment), M8291.0 (Ubiquitin-3aa from CT), M9802.4 (EA-92 (ChrA peptide)), M16207.4 (Pancreatic ribonuclease), M14092.7 (Transthyretin S-glutathionylated), M13904.7 (Transthyretin S-Cys/S-CysGly), M12545.9 (Cystatin-C-8aa from NT), M8183.6 (Ubiquitin-4aa from CT), M5227.4, M3687.0 (Secretoneurin (ChrC/SGII peptide)), M3906.4 Vasostatin II (ChrA peptide), M14565.1 (Pancreatic ribonuclease), M6509.6 (Chromogranin B peptide), M4320.6 (A-beta 1-40), M7258.2 (Chromogranin B peptide), M17349.3 (Apolipoprotein A-II dimer), M8938.5 (C3a des-Arg), M23477.4 (Prostaglandin-D synthase), M4357.0 (Alpha-1-antichymotrypsin CT fragment), M7653.2 (Osteopontin CT fragment), M4812.5 (VGF(NCBI) peptide), M4989.4 (Thymosin beta-4-acetylated), and M7718.8 (Osteopontin CT fragment phosphorylated); and b. correlating the measurement with Alzheimer's disease status.